5. 進行性核上性麻痺 ［臨床試験数：82，薬物数：107（DrugBank：36），標的遺伝子数：60，標的パスウェイ数：90］
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||NCT00382824||September 2006||28/9/2006||Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)||Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study||Progressive Supranuclear Palsy||Dietary Supplement: Coenzyme Q10;Other: Placebo||Lahey Clinic||NULL||Completed||30 Years||N/A||All||61||N/A||United States|
|2||NCT00328874||May 2006||21/5/2006||Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy||Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy||Progressive Supranuclear Palsy||Drug: Coenzyme Q10||German Parkinson Study Group (GPS)||MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical Center||Completed||40 Years||85 Years||All||20||Phase 2||Germany|
|3||EUCTR2005-000574-40-DE||24/04/2006||24/01/2006||Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A||Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A||PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.||Product Name: Coenzym Q10 Nanodispersion|
Product Code: ASK Nr. 21972
INN or Proposed INN: Ubidecarenon
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
|Kompetenznetz Parkinson e.V.||NULL||Not Recruiting||Female: yes|
|4||NCT00532571||January 2004||18/9/2007||Effects of Coenzyme Q10 in PSP and CBD||Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study||Progressive Supranuclear Palsy;Neurological Disorders||Drug: CoQ10||Lahey Clinic||NULL||Completed||40 Years||N/A||All||Phase 2/Phase 3||United States|